The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression.
about
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesMurine Models of Splenic Marginal Zone Lymphoma: A Role for Cav1?Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathologyAssociation of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cellsGenomic data integration in chronic lymphocytic leukemia.CD38 as a prognostic marker in chronic lymphocytic leukaemia at a single New Zealand centre: patient survival in comparison to age- and sex-matched population data.Evidences showing wide presence of small genomic aberrations in chronic lymphocytic leukemiaIn vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cellsHS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses.MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells.Molecular detection of the G(-248)A BAX promoter nucleotide change in B cell chronic lymphocytic leukaemiaIn vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia.Predicting survival in chronic lymphocytic leukemia.Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant?State-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia.CD38 as a prognostic marker in CLL.CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells.Recent advances in chronic lymphocytic leukemia.Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia.Genomic complexity identifies patients with aggressive chronic lymphocytic leukemiaBiology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes.FISH panels for hematologic malignancies.Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results.Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progressionBendamustine therapy in chronic lymphocytic leukemia.Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance.Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells.Surface profiles for subclassification of chronic lymphocytic leukemia.Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia.c-Cbl interacts with CD38 and promotes retinoic acid-induced differentiation and G0 arrest of human myeloblastic leukemia cells.Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.Heterogeneous intracellular expression of B-cell receptor components in B-cell chronic lymphocytic leukaemia (B-CLL) cells and effects of CD79b gene transfer on surface immunoglobulin levels in a B-CLL-derived cell line.CD11b immunophenotyping identifies inflammatory profiles in the mouse and human lungs.Comparison of Bcl-2, CD38 and ZAP-70 Expression in Chronic Lymphocytic Leukemia.Highly purified CD38 sub-populations show no evidence of preferential clonal evolution despite having increased proliferative activity when compared with CD38 sub-populations derived from the same chronic lymphocytic leukaemia patient.Phase II study of theophylline in chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E4998).A set of commercially available fluorescent in-situ hybridization probes efficiently detects cytogenetic abnormalities in patients with chronic lymphocytic leukemia.
P2860
Q24616084-CEE08F54-8CC1-47F3-95CA-66C21227D542Q28070123-8F03DC2A-FAF4-4FD9-B95B-4C23344D70F9Q28287124-13CC3172-6686-44D5-9D54-64EF59161F55Q28744086-0B671ADF-3CEF-4419-9FE3-A240816A46C2Q31147488-6A995860-63EC-4F68-A7F6-56DA0765DF8DQ33517828-94A385EC-E65F-431F-BDC1-A6BF6C66970BQ33776198-599B6E79-7B92-48FB-AFD0-61A27033AE35Q33830733-6D8231D1-B055-42AA-B2BE-3B6CC0799686Q33831931-3CCF6E4D-3724-45BD-B812-9A905C7F82B3Q33847322-800EC71D-17E8-48BD-8F8F-14DDEF80429EQ33919200-02CE4B98-8572-489D-A344-8A1EC089E9BEQ34078726-043F34A5-86FD-433D-8BC7-567740755627Q34257190-7F11D34A-79BD-418B-BC55-5DFD566952B4Q35102971-85E3B558-F3FF-4AB7-B22D-384B5A489372Q35819325-95F8EEE1-0AC3-472B-9266-1F19063759BBQ35860550-BC7F7CB4-B3F3-4A1C-B2B5-CDE9B1711933Q36194534-B96BD8A5-FEA8-4D43-9C90-9A25A6032BB8Q36384860-DAF72DA1-3E59-41AC-B12D-B4DB6C5A15D0Q36523498-725C45BA-6F46-428A-8AF4-9ECEA40E0C1FQ36689156-84F8EB5C-4856-4309-A15C-90A84E492B02Q36843780-1DE5A98B-FEE6-4447-A584-25DAE7757BBCQ36862781-EF2EE2DF-0022-4AB0-B31F-D9E8EF06A6CDQ36981741-77DE50FD-AC4C-4354-9FFB-FA6925F27E82Q37000296-AD21DDEA-F8BA-443A-97F5-16E5C6A9F985Q37195045-581DD4DB-B49F-4F30-B3F0-444F12A0675DQ37439573-02C0C857-2785-4B6F-A6E6-DD9BA5F7F9EFQ37519737-A169C09D-253A-4895-9681-C0A3ACAC20B3Q37588785-652CA879-38C5-4D57-9690-3D5AE18D1658Q37771664-6E7CC9A6-48CC-40E4-BA87-AC9FF90523E7Q37948956-DEC8F50A-8F3E-4AAE-BCD1-5B1196022B04Q38088354-CC4C577C-35A5-4F2B-8FC2-37799078F259Q38167332-6606622B-150E-4370-B23F-AECAA2D4EB48Q38359517-09696805-711D-4DDA-9E21-258D7760C499Q39169789-DF6C630D-A1D0-4946-B865-51A74023F2F2Q40374750-4A652853-C810-47BF-AAC3-ABBDFA3D8544Q40973485-568B6CBE-43B9-41C3-9E0D-6458B6323E13Q42134533-0900A973-FDD5-4556-81E8-F48A9D68B165Q44636663-8ABBC513-A040-41AF-A765-6C98A6AFEBB8Q45051059-4D4FFB4B-BBAB-4E5B-A9F8-8B48D8AA2BFDQ47262167-846487EE-D23D-4074-BD84-331ECE0CB4EF
P2860
The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The pattern of CD38 expression ...... t risk of disease progression.
@ast
The pattern of CD38 expression ...... t risk of disease progression.
@en
The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia
@nl
type
label
The pattern of CD38 expression ...... t risk of disease progression.
@ast
The pattern of CD38 expression ...... t risk of disease progression.
@en
The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia
@nl
prefLabel
The pattern of CD38 expression ...... t risk of disease progression.
@ast
The pattern of CD38 expression ...... t risk of disease progression.
@en
The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia
@nl
P2093
P921
P1433
P1476
The pattern of CD38 expression ...... t risk of disease progression.
@en
P2093
Daniela Gottardi
Federico Caligaris-Cappio
Giuliana Strola
Giuseppe Guida
Massimo Geuna
Stefania Stella
P304
P356
10.1182/BLOOD-2002-06-1801
P407
P577
2002-10-24T00:00:00Z